IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.527
EU - Europa 11.891
AS - Asia 7.659
SA - Sud America 1.625
AF - Africa 352
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 11
Totale 38.080
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.319
RU - Federazione Russa 2.643
SG - Singapore 2.508
CN - Cina 2.450
GB - Regno Unito 2.339
IE - Irlanda 1.685
IT - Italia 1.366
BR - Brasile 1.343
UA - Ucraina 860
VN - Vietnam 853
FR - Francia 800
SE - Svezia 800
HK - Hong Kong 626
DE - Germania 575
FI - Finlandia 379
KR - Corea 340
IN - India 189
ZA - Sudafrica 159
CA - Canada 109
BD - Bangladesh 101
NL - Olanda 98
TR - Turchia 98
AR - Argentina 94
IQ - Iraq 84
NG - Nigeria 66
JP - Giappone 63
MX - Messico 61
PL - Polonia 59
ID - Indonesia 51
ES - Italia 46
EC - Ecuador 44
AT - Austria 41
BE - Belgio 36
MA - Marocco 33
SA - Arabia Saudita 32
CL - Cile 30
CO - Colombia 30
PK - Pakistan 30
UZ - Uzbekistan 30
VE - Venezuela 29
CZ - Repubblica Ceca 27
KE - Kenya 24
PY - Paraguay 23
LT - Lituania 22
IR - Iran 20
JO - Giordania 20
EG - Egitto 18
PE - Perù 17
AU - Australia 15
KZ - Kazakistan 15
MY - Malesia 15
RS - Serbia 15
TN - Tunisia 15
NP - Nepal 14
AZ - Azerbaigian 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
CI - Costa d'Avorio 12
OM - Oman 12
AL - Albania 10
DZ - Algeria 10
BO - Bolivia 9
DO - Repubblica Dominicana 9
IL - Israele 9
PH - Filippine 9
PT - Portogallo 9
TW - Taiwan 9
EE - Estonia 8
LB - Libano 8
PS - Palestinian Territory 8
TH - Thailandia 8
BG - Bulgaria 7
EU - Europa 7
KG - Kirghizistan 7
DK - Danimarca 6
JM - Giamaica 6
LV - Lettonia 6
RO - Romania 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
AO - Angola 5
ET - Etiopia 5
GR - Grecia 5
PA - Panama 5
UY - Uruguay 5
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
LK - Sri Lanka 4
CR - Costa Rica 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
NI - Nicaragua 3
NO - Norvegia 3
BH - Bahrain 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
Totale 38.051
Salva come PNG Salva come JPEG
Città #
Fairfield 2.027
Southend 1.984
Dallas 1.940
Dublin 1.662
Singapore 1.356
Ashburn 1.207
Woodbridge 988
Chandler 810
Houston 783
Seattle 780
Wilmington 765
Moscow 737
Jacksonville 732
Santa Clara 684
Cambridge 638
Hong Kong 607
Beijing 606
Hefei 423
Ann Arbor 409
Princeton 371
San Jose 347
Seoul 339
Siena 325
The Dalles 278
Ho Chi Minh City 263
Nanjing 249
Los Angeles 227
Lauterbourg 220
Helsinki 196
Hanoi 187
Council Bluffs 175
Munich 136
Johannesburg 132
San Mateo 132
Milan 125
New York 125
São Paulo 125
Boardman 111
Buffalo 106
San Diego 106
Florence 103
Dong Ket 88
Rome 79
Shanghai 78
Nanchang 77
London 75
Orem 66
Abuja 63
Dearborn 63
Redondo Beach 56
Shenyang 56
Tokyo 51
Menlo Park 50
Bengaluru 49
Nuremberg 49
Hebei 48
Turku 48
Izmir 47
Columbus 45
San Francisco 45
Tianjin 45
Warsaw 45
Frankfurt am Main 44
Lappeenranta 41
Jiaxing 38
Stockholm 37
Kunming 36
Denver 35
Toronto 35
Brussels 34
Da Nang 34
Baghdad 33
Chicago 33
Phoenix 33
Rio de Janeiro 32
Montreal 30
Brooklyn 29
Chennai 29
Tashkent 28
Belo Horizonte 27
Changsha 27
Curitiba 27
Zhengzhou 26
Atlanta 25
Dhaka 25
Haiphong 25
Norwalk 25
Bologna 24
Brasília 23
Porto Alegre 23
Amsterdam 22
Boston 22
Guangzhou 22
Mexico City 22
Poplar 22
Turin 22
Kilburn 20
Portsmouth 20
Vienna 20
Amman 19
Totale 25.808
Salva come PNG Salva come JPEG
Nome #
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 330
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 317
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 316
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 305
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 297
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 291
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 289
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 288
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 286
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 285
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 285
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 282
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 276
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 275
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 274
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 274
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 268
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 267
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 261
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 257
Second generation proteasome inhibitors in multiple myeloma 255
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 255
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 248
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 248
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 246
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 244
Central nervous system multiple myeloma 242
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 242
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 238
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 237
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 230
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 230
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 229
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 227
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 224
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 223
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 221
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 217
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 215
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 214
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 213
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 211
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 210
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 208
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 207
FLT3 inhibitors in the management of acute myeloid leukemia 207
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 206
Treatment of smoldering multiple myeloma 206
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 206
Daratumumab efficacy in extramedullary orbital myeloma 206
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 203
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 201
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 201
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 200
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 199
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 199
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 198
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 198
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 197
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 195
An unusual presentation of chronic B-cell lymphocytic leukaemia 193
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 193
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
Evolving treatments in multiple myeloma patients with renal failure 192
Hyperlipidemia in a myeloma patient after bortezomib treatment 191
Extramedullary myeloma relapses 191
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 190
Anti CD38 monoclonal antibodies for multiple myeloma treatment 190
Predicting the clinical course of Hodgkin lymphoma 189
The effects of zoledronic acid on serum lipids in multiple myeloma patients 187
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 186
Bcr-abl peptides for chronic myeloid leukemia. 186
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 185
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 184
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 182
Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia 178
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 178
Unusual localizations of plasmacytoma 178
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 177
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region 177
Reply to “Rituximab activity in CD20-positive multiple myeloma” 176
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 176
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 175
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 174
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 172
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 172
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 170
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy 170
Central Nervous System Multiple Myeloma 170
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 170
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network) 170
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 167
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 167
Central nervous system multiple myeloma: a different cytogenetic profile 166
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up 166
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 166
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia 165
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 164
Totale 21.667
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021913 0 0 0 0 0 0 0 0 0 375 255 283
2021/20222.432 160 250 172 176 93 99 125 91 125 285 275 581
2022/20233.256 239 225 436 474 281 673 87 246 296 46 187 66
2023/20242.452 105 57 225 133 67 609 846 48 20 68 39 235
2024/20255.856 172 294 555 319 647 372 158 333 479 347 641 1.539
2025/202612.400 1.066 2.034 1.551 1.858 2.423 544 1.332 365 591 636 0 0
Totale 38.641